{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:53:41Z","timestamp":1790790821614,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.mcna.2019.09.002","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T21:12:52Z","timestamp":1574197972000},"page":"177-187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Mast Cell Activation"],"prefix":"10.1016","volume":"104","author":[{"given":"Dilawar","family":"Khokhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.mcna.2019.09.002_bib1","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1369\/0022155414545334","article-title":"Mast cell function: a new vision of an old cell","volume":"62","author":"Da silva","year":"2014","journal-title":"J\u00a0Histochem Cytochem"},{"key":"10.1016\/j.mcna.2019.09.002_bib2","doi-asserted-by":"crossref","first-page":"D1109","DOI":"10.2741\/krishnas","article-title":"The human mast cell: functions in physiology and disease","volume":"6","author":"Krishnaswamy","year":"2001","journal-title":"Front Biosci"},{"issue":"2","key":"10.1016\/j.mcna.2019.09.002_bib3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jaci.2017.06.007","article-title":"Mast cell activation syndromes","volume":"140","author":"Akin","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.mcna.2019.09.002_bib4","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.mcna.2019.09.002_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mcna.2019.09.002_bib6","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaip.2019.01.006","article-title":"Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome","volume":"7","author":"Valent","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.mcna.2019.09.002_bib7","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/all.12126","article-title":"Mast cell activation syndromes: definition and classification","volume":"68","author":"Valent","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.mcna.2019.09.002_bib8","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mcna.2019.09.002_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2019.08.023","article-title":"AAAAI mast cell disorders committee work group report: mast cell activation syndrome (MCAS) diagnosis and management","volume":"144","author":"Weiler","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.mcna.2019.09.002_bib10","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.iac.2018.04.006","article-title":"Patient perceptions in mast cell disorders","volume":"38","author":"Jennings","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"issue":"4","key":"10.1016\/j.mcna.2019.09.002_bib11","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jaip.2018.11.045","article-title":"Doctor, I think I am suffering from MCAS: differential diagnosis and separating facts from fiction","volume":"7","author":"Valent","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.mcna.2019.09.002_bib12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaip.2014.02.012","article-title":"Idiopathic anaphylaxis","volume":"2","author":"Greenberger","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.mcna.2019.09.002_bib13","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.jaip.2019.03.039","article-title":"Omalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS","volume":"7","author":"Lemal","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.mcna.2019.09.002_bib14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11882-012-0326-8","article-title":"Immunology and clinical manifestations of non-clonal mast cell activation syndrome","volume":"13","author":"Cardet","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.mcna.2019.09.002_bib15","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2006-06-028100","article-title":"Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with \u201cidiopathic\u201d anaphylaxis","volume":"110","author":"Akin","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mcna.2019.09.002_bib16","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2010.02.019","article-title":"Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms","volume":"125","author":"Alvarez-twose","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.mcna.2019.09.002_bib17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.iac.2018.04.014","article-title":"New insights into clonal mast cell disorders including mastocytosis","volume":"38","author":"Volertas","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.mcna.2019.09.002_bib18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1756-8722-4-10","article-title":"Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options","volume":"4","author":"Molderings","year":"2011","journal-title":"J\u00a0Hematol Oncol"},{"issue":"2","key":"10.1016\/j.mcna.2019.09.002_bib19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.iac.2015.01.010","article-title":"Mast cell activation syndromes presenting as anaphylaxis","volume":"35","author":"Akin","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"issue":"2 Suppl","key":"10.1016\/j.mcna.2019.09.002_bib20","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.anai.2010.08.005","article-title":"The basics of histamine biology","volume":"106","author":"Lieberman","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.mcna.2019.09.002_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/164_2017_18","article-title":"Histamine release from mast cells and basophils","volume":"241","author":"Borriello","year":"2017","journal-title":"Handb Exp Pharmacol"},{"issue":"3","key":"10.1016\/j.mcna.2019.09.002_bib22","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.iac.2006.05.005","article-title":"Mast cell mediators in allergic inflammation and mastocytosis","volume":"26","author":"Castells","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.mcna.2019.09.002_bib23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/iid3.94","article-title":"Prostaglandin D2 metabolites as a biomarker of in\u00a0vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis","volume":"4","author":"Cho","year":"2016","journal-title":"Immun Inflamm Dis"},{"issue":"24","key":"10.1016\/j.mcna.2019.09.002_bib24","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1056\/NEJM198012113032405","article-title":"Increased production of prostaglandin D2 in patients with systemic mastocytosis","volume":"303","author":"Roberts","year":"1980","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mcna.2019.09.002_bib25","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","article-title":"Prostaglandins and inflammation","volume":"31","author":"Ricciotti","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Suppl","key":"10.1016\/j.mcna.2019.09.002_bib26","doi-asserted-by":"crossref","first-page":"S423","DOI":"10.1194\/jlr.R800094-JLR200","article-title":"Prostanoids in health and disease","volume":"50","author":"Smyth","year":"2009","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.mcna.2019.09.002_bib27","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaip.2014.06.011","article-title":"Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11\u03b2-prostaglandin2\u03b1","volume":"2","author":"Ravi","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"11","key":"10.1016\/j.mcna.2019.09.002_bib28","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1292\/jvms.16-0347","article-title":"Discovery of anti-inflammatory role of prostaglandin D","volume":"78","author":"Murata","year":"2016","journal-title":"J\u00a0Vet Med Sci"},{"key":"10.1016\/j.mcna.2019.09.002_bib29","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.bi.52.070183.002035","article-title":"Leukotrienes","volume":"52","author":"Hammarstr\u00f6m","year":"1983","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.mcna.2019.09.002_bib30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejphar.2015.02.014","article-title":"Leukotriene C4 induces bronchoconstriction and airway vascular hyperpermeability via the cysteinyl leukotriene receptor 2 in S-hexyl glutathione-treated guinea pigs","volume":"754","author":"Yonetomi","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.mcna.2019.09.002_bib31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejphar.2015.07.017","article-title":"Non-IgE mediated mast cell activation","volume":"778","author":"Yu","year":"2016","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1016\/j.mcna.2019.09.002_bib32","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00418-018-1659-8","article-title":"Tryptase as a polyfunctional component of mast cells","volume":"149","author":"Atiakshin","year":"2018","journal-title":"Histochem Cell Biol"},{"issue":"7","key":"10.1016\/j.mcna.2019.09.002_bib33","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1365-2044.2004.03757.x","article-title":"Mast cell tryptase: a review of its physiology and clinical significance","volume":"59","author":"Payne","year":"2004","journal-title":"Anaesthesia"},{"issue":"4 Pt 2","key":"10.1016\/j.mcna.2019.09.002_bib34","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0091-6749(05)80222-2","article-title":"Tryptase, a mediator of human mast cells","volume":"86","author":"Schwartz","year":"1990","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.mcna.2019.09.002_bib35","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0145-2126(01)00020-0","article-title":"Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders","volume":"25","author":"Schwartz","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.mcna.2019.09.002_bib36","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1172\/JCI118337","article-title":"The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis","volume":"96","author":"Schwartz","year":"1995","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.mcna.2019.09.002_bib37","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000501079","article-title":"Why the 20%\u00a0+ 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome","volume":"180","author":"Valent","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.mcna.2019.09.002_bib38","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.mcna.2019.09.002_bib39","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1365-2249.2010.04287.x","article-title":"Raised tryptase without anaphylaxis or mastocytosis: heterophilic antibody interference in the serum tryptase assay","volume":"163","author":"Sargur","year":"2011","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"10.1016\/j.mcna.2019.09.002_bib40","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.beem.2013.05.011","article-title":"Heterophilic antibody interference in immunometric assays","volume":"27","author":"Bolstad","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.mcna.2019.09.002_bib41","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1056\/NEJMcpc1013929","article-title":"Case records of the Massachusetts General Hospital. Case 9-2011. A 37-year-old man with flushing and hypotension","volume":"364","author":"Murali","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.mcna.2019.09.002_bib42","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00210-016-1247-1","article-title":"Pharmacological treatment options for mast cell activation disease","volume":"389","author":"Molderings","year":"2016","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"9","key":"10.1016\/j.mcna.2019.09.002_bib43","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/all.12672","article-title":"H1-antihistamines for primary mast cell activation syndromes: a systematic review","volume":"70","author":"Nurmatov","year":"2015","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.mcna.2019.09.002_bib44","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000144042","article-title":"Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production","volume":"147","author":"Butterfield","year":"2008","journal-title":"Int Arch Allergy Immunol"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712519301038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712519301038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T17:49:39Z","timestamp":1574444979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712519301038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0025712519301038"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2019.09.002","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mast Cell Activation","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2019.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}